Date: 2016-04-05
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: Boehringer Ingelheim (Germany)
Product: BI 1026706
Action mechanism:
Disease: macular edema
Therapeutic area: Ophtalmological diseases
Country: Belgium, France, Germany, Greece, Hungary, Portugal, Spain, UK
Trial
details: This study is a proof of mechanism trial to explore the effect of BI 1026706 on the central retinal thickness and to evaluate safety and tolerability of BI 1026706 administered orally for 12 weeks in patients with mild vision impairment due to center-involved DME. (NCT02732951)
Latest
news: * On April 5, 2016, a Phase 2 trial sponsored by Boehringer Ingelheim was published on the NIH website ClinicalTrials.gov for BI 1026706 and is currently recruiting participants.
